Cook Lab

Kiri Cook MD

Kiri Cook, M.D. is an assistant professor and director of clinical research in the Department of Radiation Medicine.  She loves to care for patients in clinic and her primary focus is in the area of breast cancer.  However she also maintains a passion for research, having received the Radiological Society of North America Research Award during her residency training, which she completed at the University of California, Los Angeles.  She participates in numerous cooperative groups as a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and SWOG.  She also serves on the Cancer Prevention and Control committee within the Knight Cancer Institute.  Her research interests focus on analyzing and improving the patient’s experience during treatment.  She has particular interests in patient-reported outcomes research, patient education, and supportive care.

  • Assessing the impact of visual educational materials on women receiving radiation therapy for breast cancer
  • Implementation of a private screening checklist to identify sensitive needs in patients with cancer
  • Using patient feedback to analyze factors that affect decision making in patients with multiple treatment options

Distancing Without Isolating—Connection in the Era of COVID-19. Cook KA, Kahn JM. JAMA Oncol. Published online July 23, 2020. doi:10.1001/jamaoncol.2020.2725

Comparison of Clinical Outcomes Stratified by Target Delineation for Patients Undergoing Stereotactic Body Radiotherapy for Spinal Metastases. Attiah M, Sandler K, Medina R, Gaonkar B, McArthur D, Farha G, Selch M, De Salles A, Tenn S, Agazaryan N, Lee P, Steinberg M, Lu D, Macyszyn L, Kaprealian T. World Neurosurg. 2020 Apr;136:e68-e74. doi: 10.1016/j.wneu.2019.10.094. Epub 2019 Nov 13.

Additional Lumpectomy and Irradiation for In-Breast Recurrence of Cancer-When Less Is More. Cook K, DiNome M. JAMA Oncol. 2019 Nov 21. doi: 0.1001/jamaoncol.2019.4319. [Epub ahead of print] No abstract available.

Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C Jr, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Eur Urol. 2020 Jan;77(1):3-10. doi: 10.1016/j.eururo.2019.03.022. Epub 2019 Apr 13.

Dramatic polarization in genitourinary expert opinions regarding the clinical utility of positron emission tomography (PET) imaging in prostate cancer. Sandler KA, McClelland S 3rd, Degnin C, Chen Y, Mitin T. Int Braz J Urol. 2019 Jan-Feb;45(1):23-31. doi: 10.1590/S1677-5538.IBJU.2018.0208.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR. JAMA Oncol. 2019 Jan 1;5(1):91-96. doi: 10.1001/jamaoncol.2018.3732.

 Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists. McClelland S III, Sandler KA, Degnin C, Chen Y, Hung AY, Mitin TE. Int Braz J Urol. 2019 Mar-Apr;45(2):273-287. doi: 10.1590/S1677-5538.IBJU.2018.0275.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. Kishan AU, Chu FI, King CR, Seiferheld W, Spratt DE, Tran P, Wang X, Pugh SE, Sandler KA, Bolla M, Maingon P, De Reijke T, Nickols NG, Rettig M, Drakaki A, Liu ST, Reiter RE, Chang AJ, Feng FY, Sajed D, Nguyen PL, Kupelian PA, Steinberg ML, Boutros PC, Elashoff D, Collette L, Sandler HM. Eur Urol. 2020 Feb;77(2):201-208. doi: 10.1016/j.eururo.2019.10.008. Epub 2019 Nov 10.

Adjuvant vs. salvage radiation therapy in men with high-risk features after radical prostatectomy: Survey of North American genitourinary expert radiation oncologists. McClelland S 3rd, Sandler KA, Degnin C, Chen Y, Mitin T. Can Urol Assoc J. 2019 May;13(5):E132-E134. doi: 10.5489/cuaj.5470. Epub 2018 Oct 15.

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. JAMA. 2018 Mar 6;319(9):896-905. doi: 10.1001/jama.2018.0587.

68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, Chu FI, King CR, Steinberg ML, Rauscher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG. J Nucl Med. 2018 Feb;59(2):230-237. doi: 10.2967/jnumed.117.201749. Epub 2017 Nov 9.

Active Surveillance for Low and Intermediate Risk Prostate Cancer: Opinions of North American Genitourinary Oncology Expert Radiation Oncologists. McClelland S 3rd, Sandler KA, Degnin C, Chen Y, Mitin T. Clin Genitourin Cancer. 2018 Apr;16(2):e323-e325. doi: 10.1016/j.clgc.2017.10.021. Epub 2017 Nov 7.

Dramatically Polarized Opinion on the Role of Brachytherapy Boost in Management of High-risk Prostate Cancer: A Survey of North American Genitourinary Expert Radiation Oncologists. McClelland S 3rd, Sandler KA, Degnin C, Chen Y, Mitin T. Clin Genitourin Cancer. 2018 Jun;16(3):e543-e545. doi: 10.1016/j.clgc.2018.01.001. Epub 2018 Feb 2.

A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. Sandler KA, Abtin F, Suh R, Cook RR, Felix C, Lee JM, Garon EB, Wu J, Luterstein EM, Agazaryan N, Tenn SE, Lee C, Steinberg ML, Lee P. Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):564-573. doi: 10.1016/j.ijrobp.2018.03.011. Epub 2018 Mar 21.

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):883-888. doi: 10.1016/j.ijrobp.2018.03.060. Epub 2018 Apr 5.

Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. Sandler KA, Mitchell SA, Basch E, Raldow AC, Steinberg ML, Sharif J, Cook RR, Kupelian PA, McCloskey SA. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):44-52. doi: 10.1016/j.ijrobp.2018.04.048. Epub 2018 Jun 5.

Treatment trends for patients with brain metastases: Does practice reflect the data? Sandler KA, Shaverdian N, Cook RR, Kishan AU, King CR, Yang I, Steinberg ML, Lee P. Cancer. 2017 Jun 15;123(12):2274-2282. doi: 10.1002/cncr.30607. Epub 2017 Feb 8.

Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies. Mesko S, Sandler K, Cohen J, Konecny G, Steinberg M, Kamrava M. Int J Gynecol Cancer. 2017 Feb;27(2):403-408. doi: 10.1097/IGC.0000000000000869.

Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma. Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P. Adv Radiat Oncol. 2016 Oct 29;1(4):237-243. doi: 10.1016/j.adro.2016.10.008. eCollection 2016 Oct-Dec.

Feasibility and Initial Dosimetric Findings for a Randomized Trial Using Dose-Painted Multiparametric Magnetic Resonance Imaging-Defined Targets in Prostate Cancer. Bossart EL, Stoyanova R, Sandler K, Studenski M, Orman A, Abramowitz M, Pollack A. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):827-34. doi: 10.1016/j.ijrobp.2016.01.052. Epub 2016 Feb 4.

Post-radiotherapy prostate biopsies reveal heightened apex positivity relative to other prostate regions sampled. Huang KT, Stoyanova R, Walker G, Sandler K, Studenski MT, Dogan N, Al-Saleem T, Buyyounouski MK, Horwitz EM, Pollack A. Radiother Oncol. 2015 Apr;115(1):101-6. doi: 10.1016/j.radonc.2015.03.006. Epub 2015 May 8.

Multiparametric-MRI and Targeted Biopsies in the Management of Prostate Cancer Patients on Active Surveillance. Sandler K, Patel M, Lynne C, Parekh DJ, Punnen S, Jorda M, Casillas J, Pollack A, Stoyanova R. Front Oncol. 2015 Jan 26;5:4. doi: 10.3389/fonc.2015.00004. eCollection 2015.

 Delineation and visualization of prostate cancer in multiparametric MRI. Stoyanova R, Sandler K, Pollack A. Pract Radiat Oncol. 2013 Apr-Jun;3(2 Suppl 1):S30-1. doi: 10.1016/j.prro.2013.01.105. Epub 2013 Mar 25. No abstract available.